Oxford, UK; 04 October 2019: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, announces that Charles Swingland is recovering from a recent period of ill health which may take a number of weeks. In light of this, the Board has appointed Dr Annalisa Jenkins MBBS FRCP, Independent Non-Executive Director, as Acting Non-Executive Chair of the Board, effective immediately.
Annalisa has a degree in Medicine from St. Bartholomew’s Hospital, served as a medical officer in the British Navy and was a specialist registrar in Cardiovascular Medicine with the NHS. Her previous roles include SVP and Head of Global Medical at Bristol Myers Squibb, Head of Global R&D at Merck Serono and CEO of Dimension Therapeutics, a Nasdaq listed company that was acquired by Ultragenyx in 2017.
Annalisa is an experienced non-executive and currently chairs the boards of Cell Medica Limited, Vium Inc. and Cocoon Biotech Inc. She holds non-executive positions at the following publicly-listed companies: Ardelyx, Inc., Oncimmune Holdings plc, AVROBIO, Inc. and AgeX Therapeutics, Inc. Annalisa is also a committee member of the Science Board of US FDA and Chair of the Court of the London School of Hygiene and Tropical Medicine.
sensyne-health